TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Sponsor: Toray Industries, Inc · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 146 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT06038578 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06038578 Rescue Dossier →